The International Association for the Study of Lung Cancer Lung Cancer Staging Project Hisao Asamura, MD, Kari Chansky, MS, John Crowley, PhD, Peter.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of.

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer Ramón Rami-Porta, MD, FETCS,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee Harvey I. Pass, MD, Dorothy Giroux, MS, Catherine.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming.

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) Primo N. Lara,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Early Stage Lung Cancer: Progress in the Last 40 Years

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Mitotic Inhibitors Journal of Thoracic Oncology

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for.

Multiple Primary Cancers or Multiple Metastases, That Is the Question

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho- Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Phase I Study of Lenalidomide in Solid Tumors

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report Patrick M. Forde, MD,

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

IASLC 6th Latin American Conference on Lung Cancer

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database Valerie W. Rusch, MD, Dorothy Giroux, Catherine.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

The IASLC Lung Cancer Staging Project

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Presentation transcript:

The International Association for the Study of Lung Cancer Lung Cancer Staging Project Hisao Asamura, MD, Kari Chansky, MS, John Crowley, PhD, Peter Goldstraw, MBChB, FRCS, Valerie W. Rusch, MD, Johan F. Vansteenkiste, MD, Hirokazu Watanabe, MD, Yi-Long Wu, MD, Marcin Zielinski, MD, David Ball, MD, Ramon Rami-Porta, MD Journal of Thoracic Oncology Volume 10, Issue 12, Pages 1675-1684 (December 2015) DOI: 10.1097/JTO.0000000000000678 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Survival curves for cN0, cN1, cN2, and cN3, T-any M0 tumors. The differences of survival between neighboring categories are all statistically significant (p values: between cN0 and cN1, p < 0.0001; between cN1 and cN2, p < 0.0001; between cN2 and cN3, p < 0.0001). Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Survival curves for cN0, cN1, cN2, and cN3 according to T categories (T1–4). The differences in survival between neighboring categories are all statistically significant. Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival curves for pN0, pN1, pN2, and pN3, T-any M0 tumors according to R0 and any R settings. For both settings, the differences in survival between neighboring categories are all statistically significant (for a R0 setting: between pN0 and pN1, p < 0.0001; between pN1 and pN2, p < 0.0001; between pN2 and pN3, p = 0.0007, for any R setting: between pN0 and pN1, p < 0.0001; between pN1 and pN2, p < 0.0001; between pN2 and pN3, p < 0.0001). Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Survival curves for pN0, pN1, pN2, and pN3 in T1–4 M0 R0 resected tumors. The differences in survival between neighboring categories are all statistically significant. In T4, the differences in the survival curves among the neighboring pN categories are diminished. Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Survival curves for pN0, pN1, pN2, and pN3 T-any M0, R0 resected tumors according to geographic sources of data. Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Exploratory analyses of survival in pN1 and pN2 according to the number of metastatic nodal stations (single versus multiple) for R0 and any R settings (T-any M0). The pN1 category is divided into pN1 single (N1a) and pN1 multiple (N1b). The pN2 category is further divided into pN2 single (N2a) and pN2 multiple (N2b). Despite their different categories, the survival curves for pN1b and pN2a overlap, with 5-year survival rates of 50% and 49% for R0 resection, respectively. Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Exploratory analyses of survival for pN1 and pN2 according to the number of metastatic nodal stations (single versus multiple, skip metastasis versus nonskip metastasis) for R0 and any R settings (T-any M0). pN1 is divided into pN1 single (N1a) and pN1 multiple (N1b). The pN2 category is further divided into pN2 single with skip metastasis (N2a1), pN2 single with N1 metastasis (N2a2), and pN2-multiple (N2b). There was no statistically significant difference in survival between pN1b and pN2a1, with 5-year survival rates of 50% and 52% for R0 resection, respectively. Journal of Thoracic Oncology 2015 10, 1675-1684DOI: (10.1097/JTO.0000000000000678) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions